Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Cognitive Performance associated to functional outcomes in stable outpatients with schizophrenia.

Zaragoza Domingo S, Bobes J, García-Portilla MP, Morralla C; EPICOG-SCH Study Group.

Schizophr Res Cogn. 2015 Apr 14;2(3):146-158. doi: 10.1016/j.scog.2015.03.002. eCollection 2015 Sep.

2.

Neurocognition as a predictor of outcome in schizophrenia in the Northern Finland Birth Cohort 1966.

Juola P, Miettunen J, Salo H, Murray GK, Ahmed AO, Veijola J, Isohanni M, Jääskeläinen E.

Schizophr Res Cogn. 2015 Sep 21;2(3):113-119. doi: 10.1016/j.scog.2015.07.001. eCollection 2015 Sep.

3.

Clinical and Cognitive Significance of Auditory Sensory Processing Deficits in Schizophrenia.

Hamilton HK, Williams TJ, Ventura J, Jasperse LJ, Owens EM, Miller GA, Subotnik KL, Nuechterlein KH, Yee CM.

Am J Psychiatry. 2018 Mar 1;175(3):275-283. doi: 10.1176/appi.ajp.2017.16111203. Epub 2017 Dec 5.

PMID:
29202656
4.

TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.

Stürup AE, Jensen HD, Dolmer S, Birk M, Albert N, Nielsen M, Hjorthøj C, Eplov L, Ebdrup BH, Mors O, Nordentoft M.

Trials. 2017 Sep 29;18(1):445. doi: 10.1186/s13063-017-2172-4.

5.

Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.

Lewis AS, van Schalkwyk GI, Bloch MH.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:45-53. doi: 10.1016/j.pnpbp.2017.01.001. Epub 2017 Jan 5. Review.

6.

Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties.

Urs NM, Gee SM, Pack TF, McCorvy JD, Evron T, Snyder JC, Yang X, Rodriguiz RM, Borrelli E, Wetsel WC, Jin J, Roth BL, O'Donnell P, Caron MG.

Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8178-E8186. Epub 2016 Dec 1.

7.

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study.

Shi C, Yao SQ, Xu YF, Shi JG, Xu XF, Zhang CP, Jin H, Yu X.

Neuropsychiatr Dis Treat. 2016 Aug 24;12:2095-104. doi: 10.2147/NDT.S112542. eCollection 2016.

8.

A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey.

Oikonomidis L, Santangelo AM, Shiba Y, Clarke FH, Robbins TW, Roberts AC.

Dev Neurobiol. 2017 Mar;77(3):328-353. doi: 10.1002/dneu.22446. Review.

9.

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Arnsten AF, Girgis RR, Gray DL, Mailman RB.

Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Review.

10.

Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses.

Bortolato B, Miskowiak KW, Köhler CA, Vieta E, Carvalho AF.

Neuropsychiatr Dis Treat. 2015 Dec 17;11:3111-25. doi: 10.2147/NDT.S76700. eCollection 2015. Review.

11.

Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia.

Cordes JS, Mathiak KA, Dyck M, Alawi EM, Gaber TJ, Zepf FD, Klasen M, Zvyagintsev M, Gur RC, Mathiak K.

Front Behav Neurosci. 2015 Jun 25;9:169. doi: 10.3389/fnbeh.2015.00169. eCollection 2015.

12.

What does schizophrenia teach us about antipsychotics?

Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M.

Can J Psychiatry. 2015 Mar;60(3 Suppl 2):S14-8. Review.

13.

Functional neuroanatomical correlates of episodic memory impairment in early phase psychosis.

Francis MM, Hummer TA, Vohs JL, Yung MG, Liffick E, Mehdiyoun NF, Radnovich AJ, McDonald BC, Saykin AJ, Breier A.

Brain Imaging Behav. 2016 Mar;10(1):1-11. doi: 10.1007/s11682-015-9357-9.

14.

Pathways Associating Childhood Trauma to the Neurobiology of Schizophrenia.

Ruby E, Polito S, McMahon K, Gorovitz M, Corcoran C, Malaspina D.

Front Psychol Behav Sci. 2014 Jan 1;3(1):1-17.

15.

Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients.

Wang J, Hu M, Guo X, Wu R, Li L, Zhao J.

Neural Regen Res. 2013 Jan 25;8(3):277-86. doi: 10.3969/j.issn.1673-5374.2013.03.011.

16.

New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.

Perez SM, Lodge DJ.

Drug Des Devel Ther. 2014 Jul 2;8:887-96. doi: 10.2147/DDDT.S42708. eCollection 2014. Review.

17.

Development of a virtual reality assessment of everyday living skills.

Ruse SA, Davis VG, Atkins AS, Krishnan KR, Fox KH, Harvey PD, Keefe RS.

J Vis Exp. 2014 Apr 23;(86). doi: 10.3791/51405.

18.

Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis.

Montalvo I, Gutiérrez-Zotes A, Creus M, Monseny R, Ortega L, Franch J, Lawrie SM, Reynolds RM, Vilella E, Labad J.

PLoS One. 2014 Feb 24;9(2):e89428. doi: 10.1371/journal.pone.0089428. eCollection 2014.

19.

The cytokine model of schizophrenia: emerging therapeutic strategies.

Girgis RR, Kumar SS, Brown AS.

Biol Psychiatry. 2014 Feb 15;75(4):292-299. doi: 10.1016/j.biopsych.2013.12.002. Epub 2013 Dec 11. Review.

20.

Perceptual Category Judgment Deficits are Related to Prefrontal Decision Making Abnormalities in Schizophrenia.

Weickert TW, Terrazas A, Bigelow LB, Apud JA, Egan MF, Weinberger DR.

Front Psychiatry. 2014 Jan 6;4:184. doi: 10.3389/fpsyt.2013.00184. eCollection 2014 Jan 6.

Supplemental Content

Support Center